JPWO2021263081A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021263081A5 JPWO2021263081A5 JP2022580102A JP2022580102A JPWO2021263081A5 JP WO2021263081 A5 JPWO2021263081 A5 JP WO2021263081A5 JP 2022580102 A JP2022580102 A JP 2022580102A JP 2022580102 A JP2022580102 A JP 2022580102A JP WO2021263081 A5 JPWO2021263081 A5 JP WO2021263081A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- encoded
- her2
- gene
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 108010002687 Survivin Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims description 9
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 102000005727 Mammaglobin A Human genes 0.000 claims description 9
- 108010031030 Mammaglobin A Proteins 0.000 claims description 9
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims description 9
- 102100034256 Mucin-1 Human genes 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
- 102000000763 Survivin Human genes 0.000 claims description 9
- -1 hTERT Proteins 0.000 claims description 9
- 101150054472 HER2 gene Proteins 0.000 claims description 8
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 101150067233 MAGEA3 gene Proteins 0.000 claims description 4
- 101150114927 MUC1 gene Proteins 0.000 claims description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
Description
読み手の注意は、本明細書と同時に提出され及び本明細書と共に公衆の閲覧に付される全ての論文及び文献並びに参照により本明細書に組み込まれる全てのそのような論文及び文献の内容に向けられる。明細書（あらゆる添付の特許請求の範囲、要約書及び図面を含む）において開示する全ての特徴は、特に明記しない限り、同一の、均等な又は同様な目的にかなう代替的な特徴に置き換えることができる。したがって、特に明記しない限り、開示した各特徴は、包括的な一連の均等な又は同様な特徴の一例にすぎない。
さらなる実施形態は以下のとおりである。
［実施形態１］
ＭＵＣ１、ＨＥＲ２、ｈＴＥＲＴ、サバイビン、ＭＡＧＥＡ３及びマンマグロビンＡからなる群から選択される遺伝子によってコードされる少なくとも３種の抗原に由来する少なくとも１つのエピトープをコードするベクターと、少なくとも１種の薬学的に許容される賦形剤とを含む免疫原性組成物。
［実施形態２］
ベクターが、ＭＵＣ１、ＨＥＲ２、ｈＴＥＲＴ、サバイビン、ＭＡＧＥＡ３及びマンマグロビンＡからなる群から選択される遺伝子によってコードされる少なくとも４種の抗原をコードする、実施形態１に記載の免疫原性組成物。
［実施形態３］
ベクターが、ＭＵＣ１、ＨＥＲ２、ｈＴＥＲＴ、サバイビン、ＭＡＧＥＡ３及びマンマグロビンＡからなる群から選択される遺伝子によってコードされる少なくとも５種の抗原をコードする、実施形態１に記載の免疫原性組成物。
［実施形態４］
ベクターが、ＭＵＣ１、ＨＥＲ２、ｈＴＥＲＴ、サバイビン、ＭＡＧＥＡ３及びマンマグロビンＡからなる群から選択される遺伝子によってコードされる少なくとも６種の抗原をコードする、実施形態１に記載の免疫原性組成物。
［実施形態５］
ＭＵＣ１遺伝子によってコードされる少なくとも１つのエピトープが、ＭＵＣ１遺伝子によってコードされる全長タンパク質を含む、実施形態１～５のいずれか１つに記載の免疫原性組成物。
［実施形態６］
ＨＥＲ２遺伝子によってコードされる少なくとも１つのエピトープが、ＨＥＲ２遺伝子によってコードされるタンパク質のアミノ酸１～６５２を含む、実施形態１～５のいずれか１つに記載の免疫原性組成物。
［実施形態７］
ＨＥＲ２遺伝子によってコードされる少なくとも１つのエピトープが、ＨＥＲ２遺伝子によってコードされるタンパク質のアミノ酸６７６～１２５４を含む、実施形態１～５のいずれか１つに記載の免疫原性組成物。
［実施形態８］
ｈＴＥＲＴ遺伝子によってコードされる少なくとも１つのエピトープが、ｈＴＥＲＴ遺伝子によってコードされるタンパク質のアミノ酸１５～１１３２を含む、実施形態１～５のいずれか１つに記載の免疫原性組成物。
［実施形態９］
ＭＡＧＥＡ３遺伝子によってコードされる少なくとも１つのエピトープが、ＭＡＧＥＡ３遺伝子によってコードされる全長タンパク質を含む、実施形態１～５のいずれか１つに記載の免疫原性組成物。
［実施形態１０］
サバイビン遺伝子によってコードされる少なくとも１つのエピトープが、サバイビン遺伝子によってコードされる全長タンパク質を含む、実施形態１～５のいずれか１つに記載の免疫原性組成物。
［実施形態１１］
各エピトープが、切断可能なスペーサー配列で分離されている、実施形態１～１０のいずれか１つに記載の免疫原性組成物。
［実施形態１２］
ベクターがＤＮＡベクターである、実施形態１～１１のいずれか１つに記載の免疫原性組成物。
［実施形態１３］
ベクターが改変ワクシニアアンカラ（ＭＶＡ）ウイルスである、実施形態１～１２のいずれか１つに記載の免疫原性組成物。
［実施形態１４］
ＭＵＣ１、ＨＥＲ２、ｈＴＥＲＴ、サバイビン、ＭＡＧＥＡ３及びマンマグロビンＡからなる群から選択される１種又は複数の抗原に対するヒト対象における抗原媒介性又はＴ細胞媒介性免疫応答を誘導する方法であって、実施形態１～１３のいずれか１つに記載の免疫原性組成物をヒト対象に投与するステップを含む方法。
［実施形態１５］
実施形態１２に記載の免疫原性組成物をヒト対象に投与するステップを含む、実施形態１４に記載の方法。
［実施形態１６］
実施形態１２に記載の免疫原性組成物の投与後に実施形態１３に記載の免疫原性組成物をヒト対象に投与するステップを更に含む、実施形態１５に記載の方法。
［実施形態１７］
実施形態１２に記載の免疫原性組成物の投与の少なくとも１５日後に実施形態１３に記載の免疫原性組成物をヒト対象に投与する、実施形態１６に記載の方法。
［実施形態１８］
実施形態１２に記載の免疫原性組成物の投与の少なくとも３０日後に実施形態１３に記載の免疫原性組成物をヒト対象に投与する、実施形態１６に記載の方法。
［実施形態１９］
ヒト対象が乳がんに罹患していない、実施形態１４～１８のいずれか１つに記載の方法。
［実施形態２０］
ヒト対象が原発性乳がんに罹患している、実施形態１４～１８のいずれか１つに記載の方法。
［実施形態２１］
ヒト対象が転移性乳がんに罹患している、実施形態１４～１８のいずれか１つに記載の方法。
［実施形態２２］
ヒト対象がステージ０、Ｉ、ＩＩ、ＩＩＩ又はＩＶの乳がんに罹患している、実施形態１４～１８のいずれか１つに記載の方法。
［実施形態２３］
ヒト対象が化学療法を受けていない、実施形態１４～２２のいずれか１つに記載の方法。
The reader's attention is directed to all articles and documents filed contemporaneously with this specification and open to public inspection herewith, and to the contents of all such articles and documents incorporated herein by reference. All features disclosed in the specification (including any accompanying claims, abstracts and drawings) may be replaced by alternative features serving the same, equivalent or similar purpose, unless otherwise stated. Thus, unless otherwise stated, each disclosed feature is only one example of a generic series of equivalent or similar features.
Further embodiments are as follows.
[Embodiment 1]
An immunogenic composition comprising a vector encoding at least one epitope derived from at least three antigens encoded by genes selected from the group consisting of MUC1, HER2, hTERT, survivin, MAGEA3 and mammaglobin A, and at least one pharma- ceutically acceptable excipient.
[Embodiment 2]
The immunogenic composition of embodiment 1, wherein the vector encodes at least four antigens encoded by genes selected from the group consisting of MUC1, HER2, hTERT, survivin, MAGEA3 and mammaglobin A.
[Embodiment 3]
The immunogenic composition of embodiment 1, wherein the vector encodes at least five antigens encoded by genes selected from the group consisting of MUC1, HER2, hTERT, survivin, MAGEA3 and mammaglobin A.
[Embodiment 4]
The immunogenic composition of embodiment 1, wherein the vector encodes at least six antigens encoded by genes selected from the group consisting of MUC1, HER2, hTERT, survivin, MAGEA3 and mammaglobin A.
[Embodiment 5]
6. The immunogenic composition of any one of embodiments 1 to 5, wherein the at least one epitope encoded by the MUC1 gene comprises the full-length protein encoded by the MUC1 gene.
[Embodiment 6]
6. The immunogenic composition of any one of embodiments 1 to 5, wherein the at least one epitope encoded by the HER2 gene comprises amino acids 1 to 652 of the protein encoded by the HER2 gene.
[Embodiment 7]
6. The immunogenic composition of any one of embodiments 1 to 5, wherein at least one epitope encoded by the HER2 gene comprises amino acids 676 to 1254 of the protein encoded by the HER2 gene.
[Embodiment 8]
6. The immunogenic composition of any one of embodiments 1 to 5, wherein at least one epitope encoded by the hTERT gene comprises amino acids 15 to 1132 of the protein encoded by the hTERT gene.
[Embodiment 9]
6. The immunogenic composition of any one of embodiments 1 to 5, wherein the at least one epitope encoded by the MAGEA3 gene comprises the full-length protein encoded by the MAGEA3 gene.
[Embodiment 10]
6. The immunogenic composition of any one of embodiments 1 to 5, wherein the at least one epitope encoded by the survivin gene comprises the full-length protein encoded by the survivin gene.
[Embodiment 11]
11. The immunogenic composition of any one of embodiments 1 to 10, wherein each epitope is separated by a cleavable spacer sequence.
[Embodiment 12]
12. The immunogenic composition of any one of embodiments 1 to 11, wherein the vector is a DNA vector.
[Embodiment 13]
13. The immunogenic composition of any one of embodiments 1 to 12, wherein the vector is a Modified Vaccinia Ankara (MVA) virus.
[Embodiment 14]
14. A method of inducing an antigen-mediated or T cell-mediated immune response in a human subject against one or more antigens selected from the group consisting of MUC1, HER2, hTERT, survivin, MAGEA3 and mammaglobin A, comprising administering to the human subject an immunogenic composition according to any one of embodiments 1 to 13.
[Embodiment 15]
15. The method of embodiment 14, comprising administering the immunogenic composition of embodiment 12 to a human subject.
[Embodiment 16]
16. The method of embodiment 15, further comprising administering to a human subject the immunogenic composition of embodiment 13 after administration of the immunogenic composition of embodiment 12.
[Embodiment 17]
The method of embodiment 16, wherein the immunogenic composition of embodiment 13 is administered to the human subject at least 15 days after administration of the immunogenic composition of embodiment 12.
[Embodiment 18]
The method of embodiment 16, wherein the immunogenic composition of embodiment 13 is administered to the human subject at least 30 days after administration of the immunogenic composition of embodiment 12.
[Embodiment 19]
The method of any one of embodiments 14-18, wherein the human subject is not afflicted with breast cancer.
[Embodiment 20]
The method of any one of embodiments 14-18, wherein the human subject is afflicted with primary breast cancer.
[Embodiment 21]
The method of any one of embodiments 14-18, wherein the human subject is afflicted with metastatic breast cancer.
[Embodiment 22]
The method of any one of embodiments 14-18, wherein the human subject is afflicted with stage 0, I, II, III or IV breast cancer.
[Embodiment 23]
The method of any one of embodiments 14-22, wherein the human subject is chemotherapy naive.
Claims (13)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044675P | 2020-06-26 | 2020-06-26 | |
| US63/044,675 | 2020-06-26 | ||
| PCT/US2021/039046 WO2021263081A2 (en) | 2020-06-26 | 2021-06-25 | Breast cancer vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533204A JP2023533204A (en) | 2023-08-02 |
| JPWO2021263081A5 true JPWO2021263081A5 (en) | 2024-07-02 |
Family
ID=79281909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580102A Pending JP2023533204A (en) | 2020-06-26 | 2021-06-25 | breast cancer vaccine |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230233656A1 (en) |
| EP (1) | EP4171619A2 (en) |
| JP (1) | JP2023533204A (en) |
| AU (1) | AU2021294322A1 (en) |
| CA (1) | CA3183774A1 (en) |
| WO (1) | WO2021263081A2 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| AU2014343813B2 (en) * | 2013-10-28 | 2020-02-27 | Invectys | A telomerase encoding DNA vaccine |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US11154599B2 (en) * | 2015-05-18 | 2021-10-26 | Oncoqr Ml Gmbh | Her2/neu immunogenic composition |
| US20210196809A1 (en) * | 2017-03-09 | 2021-07-01 | President And Fellows Of Harvard College | Cancer vaccine |
| CN110790840A (en) * | 2018-08-01 | 2020-02-14 | 三生国健药业（上海）股份有限公司 | Antibodies that bind to human HER2, methods of making and uses thereof |
-
2021
- 2021-06-25 WO PCT/US2021/039046 patent/WO2021263081A2/en unknown
- 2021-06-25 US US18/012,432 patent/US20230233656A1/en active Pending
- 2021-06-25 CA CA3183774A patent/CA3183774A1/en active Pending
- 2021-06-25 JP JP2022580102A patent/JP2023533204A/en active Pending
- 2021-06-25 AU AU2021294322A patent/AU2021294322A1/en active Pending
- 2021-06-25 EP EP21828216.8A patent/EP4171619A2/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ellis | New technologies for making vaccines | |
| US6168793B1 (en) | Heat shock protein 70 preparations in vaccination against cancer and infectious disease | |
| US20200246443A1 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
| KR100877759B1 (en) | Fusion protein for inhibiting cervical cancer | |
| Golovliov et al. | Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis | |
| Colmenero et al. | Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene | |
| JP2023524916A (en) | Tumor treatment with combination of oncolytic virus and immune checkpoint inhibitor | |
| US10702591B2 (en) | Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-beta-hydroxylase | |
| CN105246496A (en) | Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT-1 | |
| JP2004507231A5 (en) | ||
| CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
| CA2431188A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
| CN107058231A (en) | Carry recombined adhenovirus of antigen-4 fusion protein gene and its preparation method and application | |
| US20140271689A1 (en) | Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase) | |
| JPWO2021263081A5 (en) | ||
| CN1517437B (en) | Vaccine for specificity treating tumour or endocellular infection and application | |
| CN105176957A (en) | Complexes formed by RCC (renal cell carcinoma) related peptide and HSPs (heat shock proteins) as well as applications of complexes | |
| WO2004108156A1 (en) | A INTRACUTANEOUS INJECTION COMBINED VACCINE INCLUDED HeVac AND BCG AND ITS PREPARATION METHOD | |
| Adamina et al. | Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy | |
| CN114805607B (en) | EGFRvIII-PDL1-GMCSF tumor vaccine and preparation method and application thereof | |
| Carroll et al. | Poxviruses as vectors for cancer immunotherapy | |
| AU2006337522A1 (en) | Method for producing epitomers and their uses on carrier microorganisms | |
| WO2023187366A1 (en) | Immunogenic compositions for the prevention of influenza a | |
| Cai | Emerging role of vaccines in cancer therapies | |
| ES2353857T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT IMPROVE THE IMMUNOGENICITY OF LITTLE IMMUNOGENIC ANTIGENS. |